CN105902501B - 一种头孢丙烯干混悬剂及其制备方法和应用 - Google Patents
一种头孢丙烯干混悬剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN105902501B CN105902501B CN201610312573.7A CN201610312573A CN105902501B CN 105902501 B CN105902501 B CN 105902501B CN 201610312573 A CN201610312573 A CN 201610312573A CN 105902501 B CN105902501 B CN 105902501B
- Authority
- CN
- China
- Prior art keywords
- cefprozil
- dry suspension
- dry
- preparation
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 title claims abstract description 97
- 229960002580 cefprozil Drugs 0.000 title claims abstract description 97
- 239000000725 suspension Substances 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 38
- 239000000843 powder Substances 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 18
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000796 flavoring agent Substances 0.000 claims abstract description 14
- 235000019634 flavors Nutrition 0.000 claims abstract description 14
- 235000015205 orange juice Nutrition 0.000 claims abstract description 13
- 108010011485 Aspartame Proteins 0.000 claims abstract description 12
- 239000000605 aspartame Substances 0.000 claims abstract description 12
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 12
- 235000010357 aspartame Nutrition 0.000 claims abstract description 12
- 229960003438 aspartame Drugs 0.000 claims abstract description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 11
- 229930195725 Mannitol Natural products 0.000 claims abstract description 11
- 239000000594 mannitol Substances 0.000 claims abstract description 11
- 235000010355 mannitol Nutrition 0.000 claims abstract description 11
- 238000005469 granulation Methods 0.000 claims abstract description 9
- 230000003179 granulation Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 17
- 238000007908 dry granulation Methods 0.000 claims description 10
- 235000020985 whole grains Nutrition 0.000 claims description 7
- 238000005096 rolling process Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 19
- 235000019640 taste Nutrition 0.000 abstract description 10
- 239000012467 final product Substances 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 22
- 238000012216 screening Methods 0.000 description 21
- 239000000375 suspending agent Substances 0.000 description 19
- 238000004062 sedimentation Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 235000003599 food sweetener Nutrition 0.000 description 10
- 239000003765 sweetening agent Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000011812 mixed powder Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000230 xanthan gum Substances 0.000 description 7
- 235000010493 xanthan gum Nutrition 0.000 description 7
- 229920001285 xanthan gum Polymers 0.000 description 7
- 229940082509 xanthan gum Drugs 0.000 description 7
- 239000012535 impurity Substances 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 239000004384 Neotame Substances 0.000 description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 235000019412 neotame Nutrition 0.000 description 5
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 5
- 108010070257 neotame Proteins 0.000 description 5
- 238000005453 pelletization Methods 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 2
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 240000008005 Crotalaria incana Species 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 glidant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 235000019590 thick flavour Nutrition 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
处方 | 实验结果 |
处方14 | 溶液澄清,苦味未完全掩盖,橙香味不明显。 |
处方15 | 溶液澄清,苦味未完全掩盖,橙香味不明显。 |
处方16 | 溶液澄清,甜度适中,气味芳香,可掩盖主药的臭味。 |
处方17 | 8人觉得甜度适中,还有14人觉得甜度稍大,橙香味浓,可掩盖主药的臭味。 |
处方18 | 甜度适中,对口腔有麻痹感,持续数分钟,橙香味不明显。 |
处方19 | 溶液较苦,苦味未被掩盖,橙香味不明显,且溶液具有一定的涩味 |
处方20 | 甜度适中,橙香味不明显,其口感弱于处方15 |
处方21 | 甜度适中,香味不明显,不能掩盖主药的臭味 |
检测项目 | 处方28 | 处方29 | 处方30 | 处方30 | 处方31 |
休止角(θ) | 35° | 41° | 40° | 41° | 40° |
吸湿增重 | 0.08% | 0.1% | 0.12% | 2.4% | 4.8% |
口感 | 好 | 一般 | 差 | 一般 | 一般 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610312573.7A CN105902501B (zh) | 2016-05-11 | 2016-05-11 | 一种头孢丙烯干混悬剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610312573.7A CN105902501B (zh) | 2016-05-11 | 2016-05-11 | 一种头孢丙烯干混悬剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105902501A CN105902501A (zh) | 2016-08-31 |
CN105902501B true CN105902501B (zh) | 2019-02-05 |
Family
ID=56747981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610312573.7A Active CN105902501B (zh) | 2016-05-11 | 2016-05-11 | 一种头孢丙烯干混悬剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105902501B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108743548B (zh) * | 2018-06-28 | 2021-08-06 | 苏州盛达药业有限公司 | 一种头孢丙烯颗粒剂及其制备方法 |
CN110960498A (zh) * | 2019-12-25 | 2020-04-07 | 南京亿华药业有限公司 | 一种热不稳定药物组合物的制备方法 |
CN119345134B (zh) * | 2024-12-26 | 2025-03-11 | 金鸿药业股份有限公司 | 一种头孢丙烯干混悬剂的制备方法及头孢丙烯干混悬剂 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780085A (zh) * | 2010-02-26 | 2010-07-21 | 汕头金石制药总厂 | 头孢丙烯药物组合物 |
CN102038646A (zh) * | 2010-12-27 | 2011-05-04 | 山东鲁抗医药股份有限公司 | 一种无糖型头孢丙烯干混悬剂及其制备方法 |
CN102144975A (zh) * | 2010-12-24 | 2011-08-10 | 山东省医药工业研究所 | 头孢丙烯混悬药物组合物 |
CN103432076A (zh) * | 2013-07-25 | 2013-12-11 | 海南葫芦娃制药有限公司 | 头孢丙烯干混悬剂及其制备方法 |
CN105380948A (zh) * | 2015-11-27 | 2016-03-09 | 浙江华立南湖制药有限公司 | 一种双氢青蒿素哌喹干混悬剂及其制备工艺 |
-
2016
- 2016-05-11 CN CN201610312573.7A patent/CN105902501B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780085A (zh) * | 2010-02-26 | 2010-07-21 | 汕头金石制药总厂 | 头孢丙烯药物组合物 |
CN102144975A (zh) * | 2010-12-24 | 2011-08-10 | 山东省医药工业研究所 | 头孢丙烯混悬药物组合物 |
CN102038646A (zh) * | 2010-12-27 | 2011-05-04 | 山东鲁抗医药股份有限公司 | 一种无糖型头孢丙烯干混悬剂及其制备方法 |
CN103432076A (zh) * | 2013-07-25 | 2013-12-11 | 海南葫芦娃制药有限公司 | 头孢丙烯干混悬剂及其制备方法 |
CN105380948A (zh) * | 2015-11-27 | 2016-03-09 | 浙江华立南湖制药有限公司 | 一种双氢青蒿素哌喹干混悬剂及其制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN105902501A (zh) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105902501B (zh) | 一种头孢丙烯干混悬剂及其制备方法和应用 | |
CN112312893A (zh) | 奥德昔巴特的药物制剂 | |
CN101766648A (zh) | 聚乙二醇电解质颗粒制剂及其制造方法 | |
Ding et al. | Preparation and properties of modified chitosan as potential matrix materials for drug sustained-release beads | |
CN105193742A (zh) | 替比培南酯颗粒剂组合物、其制备方法及应用 | |
CN101278914A (zh) | 头孢泊肟酯干混悬剂组合物及其制备方法 | |
CN103585641A (zh) | 一种脂质包裹和环糊精包合协同矫味方法及其相关制剂 | |
CN107115312A (zh) | 一种诺氟沙星片及其制备方法 | |
CN104586814B (zh) | 一种阿瑞匹坦胶囊 | |
CN105560199B (zh) | 一种小儿多潘立酮口崩片及其制备方法 | |
CN109908104B (zh) | 一种阿莫西林胶囊及其制备方法 | |
CN102885791A (zh) | 一种制备盐酸非索非那定口腔崩解片的方法 | |
CN106018618B (zh) | 草酸艾司西酞普兰片剂组合物和质控方法 | |
CN102600083B (zh) | 一种头孢呋辛酯颗粒及其制备方法 | |
CN110548008B (zh) | 阿考替胺固体分散体及其组合物 | |
CN104473901B (zh) | 一种头孢地尼胶囊及其制备方法 | |
CN115721611B (zh) | 富马酸伏诺拉生干混悬剂及其制备方法 | |
Bakliwal et al. | FORMULATION AND EVALUATION OF NATEGLINIDE NANOSPONGES. | |
CN107661305A (zh) | 一种诺氟沙星组合物 | |
Patel et al. | Formulation and evalution of oral reconstitutable suspension of cefpodoxime proxetil | |
Asa et al. | Design and evaluation of novel sustained-release floating microspheres for oral delivery of ciprofloxacin hydrochloride | |
CN107496928A (zh) | 一种熊去氧胆酸干混悬剂及其制备方法 | |
CN103417490B (zh) | 一种含有盐酸多奈哌齐的颗粒剂及其制备方法 | |
CN108498481B (zh) | 头孢克肟组合物及其制备方法 | |
CN105769800B (zh) | 一种盐酸沙格雷酯片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170124 Address after: Mianyang City, Sichuan Province, 622651 Industrial Park Applicant after: Good Doctor Pharmaceutical Group Co., Ltd. Address before: 622651 Sichuan city of Mianyang Province County town of Hua Gai Shengkelu Applicant before: SICHUAN YUANJIAN PHARMACEUTICAL CO., LTD. |
|
CB02 | Change of applicant information |
Address after: 622651 Anzhou Industrial Park, Mianyang City, Sichuan Province Applicant after: Good Doctor Pharmaceutical Group Co., Ltd. Address before: 622651 Anzhou Industrial Park, Mianyang City, Sichuan Province Applicant before: Good Doctor Pharmaceutical Group Co., Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |